ImmuCell (ICCC) plans a controlled launch of Re-Tain, a treatment for dairy cows with subclinical mastitis, which affects milk production.

"This investigational strategy allows us to collect product performance data" while the full non-administrative new animal drug application submission is in the final stages of review, the company said Wednesday in a statement.

Clearing inspectional observations at the contract manufacturer's facilities "is still the critical path constraint" for approval, the company said.

The test marketing isn't expected to generate significant revenue or profit, the company said.